Literature DB >> 25791828

Abnormal myofiber morphology and limb dysfunction in claudication.

Panagiotis Koutakis1, Sara A Myers2, Kim Cluff3, Duy M Ha1, Gleb Haynatzki4, Rodney D McComb5, Koji Uchida6, Dimitrios Miserlis1, Evlampia Papoutsi1, Jason M Johanning7, George P Casale8, Iraklis I Pipinos9.   

Abstract

BACKGROUND: Peripheral artery disease (PAD), which affects an estimated 27 million people in Europe and North America, is caused by atherosclerotic plaques that limit blood flow to the legs. Chronic, repeated ischemia in the lower leg muscles of PAD patients is associated with loss of normal myofiber morphology and myofiber degradation. In this study, we tested the hypothesis that myofiber morphometrics of PAD calf muscle are significantly different from normal calf muscle and correlate with reduced calf muscle strength and walking performance.
METHODS: Gastrocnemius biopsies were collected from 154 PAD patients (Fontaine stage II) and 85 control subjects. Morphometric parameters of gastrocnemius fibers were determined and evaluated for associations with walking distances and calf muscle strength.
RESULTS: Compared with control myofibers, PAD myofiber cross-sectional area, major and minor axes, equivalent diameter, perimeter, solidity, and density were significantly decreased (P < 0.005), whereas roundness was significantly increased (P < 0.005). Myofiber morphometric parameters correlated with walking distances and calf muscle strength. Multiple regression analyses demonstrated myofiber cross-sectional area, roundness, and solidity as the best predictors of calf muscle strength and 6-min walking distance, whereas cross-sectional area was the main predictor of maximum walking distance.
CONCLUSIONS: Myofiber morphometrics of PAD gastrocnemius differ significantly from those of control muscle and predict calf muscle strength and walking distances of the PAD patients. Morphometric parameters of gastrocnemius myofibers may serve as objective criteria for diagnosis, staging, and treatment of PAD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Claudication; Myofiber morphology; Walking distance

Mesh:

Year:  2015        PMID: 25791828      PMCID: PMC4512658          DOI: 10.1016/j.jss.2015.02.011

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  39 in total

1.  Lack of functional benefits following infrainguinal bypass in peripheral arterial occlusive disease patients.

Authors:  A W Gardner; L A Killewich
Journal:  Vasc Med       Date:  2001       Impact factor: 3.239

2.  Prediction of claudication pain from clinical measurements obtained at rest.

Authors:  A W Gardner; J S Skinner; B W Cantwell; L K Smith
Journal:  Med Sci Sports Exerc       Date:  1992-02       Impact factor: 5.411

3.  Abnormal joint powers before and after the onset of claudication symptoms.

Authors:  Panagiotis Koutakis; Jason M Johanning; Gleb R Haynatzki; Sara A Myers; Nicholas Stergiou; G Matthew Longo; Iraklis I Pipinos
Journal:  J Vasc Surg       Date:  2010-08       Impact factor: 4.268

4.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).

Authors:  L Norgren; W R Hiatt; J A Dormandy; M R Nehler; K A Harris; F G R Fowkes
Journal:  J Vasc Surg       Date:  2007-01       Impact factor: 4.268

Review 5.  Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease.

Authors:  E P Brass; W R Hiatt
Journal:  Vasc Med       Date:  2000       Impact factor: 3.239

6.  Peripheral arterial insufficiency and the fine structure of the gastrocnemius muscle.

Authors:  B Hedberg; K A Angquist; M Sjöström
Journal:  Int Angiol       Date:  1988 Jan-Mar       Impact factor: 2.789

7.  Histochemical changes in striated muscle in patients with intermittent claudication.

Authors:  J Mäkitie; H Teräväinen
Journal:  Arch Pathol Lab Med       Date:  1977-12       Impact factor: 5.534

8.  Is percutaneous transluminal angioplasty better than exercise for claudication? Preliminary results from a prospective randomised trial.

Authors:  T S Creasy; P J McMillan; E W Fletcher; J Collin; P J Morris
Journal:  Eur J Vasc Surg       Date:  1990-04

Review 9.  Sarcopenia: pharmacology of today and tomorrow.

Authors:  Marco Brotto; Eduardo L Abreu
Journal:  J Pharmacol Exp Ther       Date:  2012-08-28       Impact factor: 4.030

10.  Oxidative damage and myofiber degeneration in the gastrocnemius of patients with peripheral arterial disease.

Authors:  Dustin J Weiss; George P Casale; Panagiotis Koutakis; Aikaterini A Nella; Stanley A Swanson; Zhen Zhu; Dimitrios Miserlis; Jason M Johanning; Iraklis I Pipinos
Journal:  J Transl Med       Date:  2013-09-25       Impact factor: 5.531

View more
  23 in total

1.  Collateral Development and Arteriogenesis in Hindlimbs of Swine After Ligation of Arterial Inflow.

Authors:  Yue Gao; Shruthi Aravind; Neesha S Patel; Matthew A Fuglestad; Joshua S Ungar; Constance J Mietus; Shuai Li; George P Casale; Iraklis I Pipinos; Mark A Carlson
Journal:  J Surg Res       Date:  2020-01-24       Impact factor: 2.192

2.  A low-cost, wireless near-infrared spectroscopy device detects the presence of lower extremity atherosclerosis as measured by computed tomographic angiography and characterizes walking impairment in peripheral artery disease.

Authors:  Matthew A Fuglestad; Hernan Hernandez; Yue Gao; Henamari Ybay; Molly N Schieber; Katyarina E Brunette; Sara A Myers; George P Casale; Iraklis I Pipinos
Journal:  J Vasc Surg       Date:  2019-08-21       Impact factor: 4.268

3.  Analysis of ischemic muscle in patients with peripheral artery disease using X-ray spectroscopy.

Authors:  Ryan A Becker; Kim Cluff; Nithyanandhi Duraisamy; George P Casale; Iraklis I Pipinos
Journal:  J Surg Res       Date:  2017-07-25       Impact factor: 2.192

4.  Peripheral artery disease affects the function of the legs of claudicating patients in a diffuse manner irrespective of the segment of the arterial tree primarily involved.

Authors:  Todd J Leutzinger; Panagiotis Koutakis; Matthew A Fuglestad; Hafizur Rahman; Holly Despiegelaere; Mahdi Hassan; Molly Schieber; Jason M Johanning; Nick Stergiou; G Matthew Longo; George P Casale; Sara A Myers; Iraklis I Pipinos
Journal:  PLoS One       Date:  2022-07-13       Impact factor: 3.752

5.  An endovascular model of ischemic myopathy from peripheral arterial disease.

Authors:  Chandler A Long; Lucas H Timmins; Panagiotis Koutakis; Traci T Goodchild; David J Lefer; Iraklis I Pipinos; George P Casale; Luke P Brewster
Journal:  J Vasc Surg       Date:  2016-09-29       Impact factor: 4.268

6.  Revascularization and muscle adaptation to limb demand ischemia in diet-induced obese mice.

Authors:  Hassan Albadawi; A Aria Tzika; Christian Rask-Madsen; Lindsey M Crowley; Michael W Koulopoulos; Hyung-Jin Yoo; Michael T Watkins
Journal:  J Surg Res       Date:  2016-06-08       Impact factor: 2.192

7.  Heat therapy improves body composition and muscle function but does not affect capillary or collateral growth in a model of obesity and hindlimb ischemia.

Authors:  Kyoungrae Kim; Bohyun Ro; Frederick W Damen; Daniel P Gramling; Trevor D Lehr; Qifan Song; Craig J Goergen; Bruno T Roseguini
Journal:  J Appl Physiol (1985)       Date:  2020-11-12

8.  A Swine Hind Limb Ischemia Model Useful for Testing Peripheral Artery Disease Therapeutics.

Authors:  Juline N Deppen; Sydney C Ginn; Na Hee Kim; Lanfang Wang; Ronald J Voll; Steven H Liang; Mark M Goodman; John N Oshinski; Rebecca D Levit
Journal:  J Cardiovasc Transl Res       Date:  2021-05-28       Impact factor: 4.132

Review 9.  Exercise for intermittent claudication.

Authors:  Risha Lane; Amy Harwood; Lorna Watson; Gillian C Leng
Journal:  Cochrane Database Syst Rev       Date:  2017-12-26

Review 10.  Skeletal Muscle Pathology in Peripheral Artery Disease: A Brief Review.

Authors:  Mary M McDermott; Luigi Ferrucci; Marta Gonzalez-Freire; Kate Kosmac; Christiaan Leeuwenburgh; Charlotte A Peterson; Sunil Saini; Robert Sufit
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-09-17       Impact factor: 10.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.